| Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? | |
| | |
MedLine Citation:
|
PMID: 20655037 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study demonstrated a significant increase in myocardial infarction events with dabigatran compared with warfarin, provoking renewed interest in whether vitamin K antagonists are useful drugs for the prevention of myocardial infarction in high-risk patients with atrial fibrillation. Present analyses examined whether there was an increased risk of myocardial infarction associated with non-warfarin anticoagulants (Stroke Prevention with the ORal direct Thrombin Inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial Fibrillation III and IV, RE-LY, Amadeus) or "anticoagulant equivalents" (Atrial fibrillation Clopidogrel Trial with Irbesartan for the prevention of Vascular Events) in patients with atrial fibrillation who are prescribed anticoagulation for stroke thromboprophylaxis. The overall annual event rate for those receiving warfarin was 0.98% compared with 1.32% for those receiving comparators. Warfarin was associated with a significant reduction in myocardial infarction (relative risk 0.77; 95% confidence interval (CI), 0.63-0.95), an effect largely driven by the RE-LY trial. Sensitivity analyses, excluding RE-LY, revealed a nonsignificant reduction in myocardial infarctions (relative risk 0.83; 95% CI, 0.62-1.10); an analogous analysis excluding the Atrial fibrillation Clopidogrel Trial with Irbesartan for the prevention of Vascular Events demonstrated a significant reduction in myocardial infarctions (relative risk 0.80; 95% CI, 0.64-1.00). Warfarin might provide a protective effect against myocardial infarction compared with non-warfarin anticoagulants or "anticoagulation equivalents" in patients with atrial fibrillation who are prescribed anticoagulation for stroke thromboprophylaxis. |
| | |
Authors:
|
Gregory Y H Lip; Deirdre A Lane |
Related Documents
:
|
18035917 - Efficacy and safety of fondaparinux in patients with acute coronary syndromes. 10478987 - Review of the fifth american college of chest physicians consensus conference on antith... 21745477 - Effects of different small hspb members on contractile dysfunction and structural chang... 16511607 - Ximelagatran. 8022047 - Determination of regional myocardial blood flow with 13n-ammonia positron emission tomo... 16641417 - In vitro evaluation of stent patency and in-stent stenoses in 10 metallic stents using ... |
Publication Detail:
|
Type: Journal Article; Meta-Analysis; Review Date: 2010-07-23 |
Journal Detail:
|
Title: The American journal of medicine Volume: 123 ISSN: 1555-7162 ISO Abbreviation: Am. J. Med. Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-08-30 Completed Date: 2010-09-13 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0267200 Medline TA: Am J Med Country: United States |
Other Details:
|
Languages: eng Pagination: 785-9 Citation Subset: AIM; IM |
Affiliation:
|
University of Birmingham Centre for Cardiovascular Sciences, Birmingham, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anticoagulants
/
therapeutic use* Atrial Fibrillation / complications* Azetidines / therapeutic use Benzimidazoles / therapeutic use Benzylamines / therapeutic use Biphenyl Compounds / therapeutic use Humans Myocardial Infarction / etiology, prevention & control* Pyridines / therapeutic use Randomized Controlled Trials as Topic Stroke / etiology, prevention & control* Tetrazoles / therapeutic use Warfarin / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 0/Azetidines; 0/Benzimidazoles; 0/Benzylamines; 0/Biphenyl Compounds; 0/Pyridines; 0/Tetrazoles; 0/ximelagatran; 138402-11-6/irbesartan; 211915-06-9/dabigatran etexilate; 81-81-2/Warfarin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Autosomal-recessive early-onset retinitis pigmentosa caused by a mutation in PDE6G, the gene encodin...
Next Document: Albizosides D and E, two new cytotoxic triterpene saponins from Albizia chinensis.